arrow
S

Satoshi Fukushima

kumamoto university
H指数:49
被引数:9,502

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Intratumoral injection of antigen-pulsed induced pluripotent stem cell-derived myeloid cells expressing interferon-β induces model antigen-specific local and systemic antitumor immunity in melanoma

抗原脉冲的诱导多能干细胞来源髓系细胞表达干扰素-β,经瘤内注射后可在黑素瘤模型中诱导抗原特异性的局部和系统性抗肿瘤免疫

2026-11-180
OAAI
Pathologic deep margin distance and prognosis in invasive acral melanoma of the sole

足底侵袭性肢端黑色素瘤的病理学深部切缘距离与预后

2026-11-020
OAAI
IL-12–producing iPSC-derived antigen-presenting cells enhance antitumor immunity and enable off-the-shelf immunotherapy

IL-12产生型iPSC衍生抗原呈递细胞增强抗肿瘤免疫并实现即用型免疫疗法

2026-10-170
PRE
Lectin-based glycoproteomics reveals a novel role of O-glycan truncation in the induction of melanogenesis

凝集素基糖蛋白质组学揭示O-糖链截短在黑色素生成诱导中的新作用

2026-09-290
OAAI
Anterior gradient 2 is overexpressed in extramammary Paget's disease and involved in cell survival

前梯度蛋白2在乳腺外佩吉特病中过表达并参与细胞生存

2026-08-220
PRE
Phase III Study Investigating the Safety and Efficacy of TM5614 in Combination With Nivolumab for the Treatment of Unresectable Malignant Melanoma: Protocol

III期研究探讨TM5614联合尼鲁单抗治疗不可切除性恶性黑色素瘤的安全性与有效性:方案

2026-01-080
PRE
Prognostic outcomes of immediate complete lymph node dissection versus observation in patients with acral melanoma of the sole with sentinel node metastasis: a retrospective, multicenter study

跖部肢端黑色素瘤患者中,对于哨兵淋巴结转移患者,即刻完全淋巴结清扫术与观察治疗的预后结局比较:一项回顾性、多中心研究

2025-12-050
PRE
Real-World Efficacy of Chemotherapy in Patients With Advanced Unresectable Extramammary Paget Disease: A Retrospective Multicenter Study of 138 Japanese Patients
2025-12-010
PRE
Whole-genome sequencing reveals rare and structural variants contributing to psoriasis and identifies CERCAM as a risk gene

全基因组测序揭示了与银屑病相关的罕见和结构变异,并确定了CERCAM为风险基因

2025-08-220
OAAI
Prognosis of a deep excision margin within or beyond subcutaneous fat for invasive acral melanoma of the sole: A multi-institutional retrospective study

足底侵袭性肢端黑色素瘤的皮下脂肪内或外深部切除边缘的预后:一项多中心回顾性研究

Surgery
IF2.7
2025-07-220
OA